BioCorRx Inc., through its subsidiaries, provides alcoholism and opioid addiction treatment program for use in rehabilitation and treatment centers in the United States. The company distributes and licenses BioCorRx recovery program, a medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant. It is also developing BICX101, an injectable naltrexone product; and BICX102, an implantable naltrexone implant for the treatment of alcohol and opioid addiction. The company distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is headquartered in Anaheim, California.
Industry, Sector and Symbol
Industry Specialty outpatient clinics, not elsewhere classified
Sub-IndustryN/A
SectorMedical
Phone714-462-4880
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$650,000.00
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date3/27/2019 (Estimated)
OptionableNot Optionable
Biocorrx (OTCMKTS:BICX) Frequently Asked Questions
What is Biocorrx's stock symbol?
Biocorrx trades on the OTCMKTS under the ticker symbol "BICX."
How were Biocorrx's earnings last quarter?
Biocorrx Inc (OTCMKTS:BICX) announced its earnings results on Thursday, November, 17th. The company reported ($0.02) earnings per share (EPS) for the quarter. The business had revenue of $0.17 million for the quarter. View Biocorrx's Earnings History.
When is Biocorrx's next earnings date?
Has Biocorrx been receiving favorable news coverage?
Media headlines about BICX stock have trended somewhat negative on Tuesday, InfoTrie Sentiment reports. The research group scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Biocorrx earned a media sentiment score of -1.1 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future.
Who are some of Biocorrx's key competitors?
Some companies that are related to Biocorrx include Lexagene (LXG), Indiva (NDVA), Mannatech (MTEX), Aquabounty Technologies (AQB), MGC Pharmaceuticals (MXC), Acerus Pharmaceuticals (ASP), TRACON Pharmaceuticals (TCON), AIT Therapeutics (AITB), Leap Therapeutics (LPTX), Avacta Group (AVCT), Zelda Therapeutics (ZLD), Helix Biopharma (HBPCF), Novus Therapeutics (NVUS), Novan (NOVN) and Aptevo Therapeutics (APVO).
What other stocks do shareholders of Biocorrx own?
Who are Biocorrx's key executives?
Biocorrx's management team includes the folowing people:
- Mr. Brady James Granier, Pres, CEO & Director (Age 47)
- Ms. Lourdes Felix, CFO, COO & Director (Age 51)
- Mr. Thomas Patrick Welch, VP of Operations
- Dr. George N. Fallieras, Medical Consultant
How do I buy shares of Biocorrx?
Shares of BICX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Biocorrx's stock price today?
One share of BICX stock can currently be purchased for approximately $3.95.
How big of a company is Biocorrx?
Biocorrx has a market capitalization of $10.27 million and generates $650,000.00 in revenue each year.
What is Biocorrx's official website?
How can I contact Biocorrx?
Biocorrx's mailing address is 2390 EAST ORANGEWOOD AVENUE SUITE 575, ANAHEIM CA, 92806. The company can be reached via phone at 714-462-4880 or via email at [email protected]
MarketBeat Community Rating for Biocorrx (OTCMKTS BICX)
MarketBeat's community ratings are surveys of what our community members think about Biocorrx and other stocks. Vote "Outperform" if you believe BICX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BICX will underperform the S&P 500 over the long term. You may vote once every thirty days.
